Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: A 3-year randomised trial

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 82, Issue 12, 2011, Pages 1344-1350

  Edan, Gilles ^a,b   Comi, G ^c,d   Le Page, E ^a   Leray, E ^a,b   Rocca, M A ^c,d   Filippi, M ^c,d  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ EUROPÉENNE DE BRETAGNE   (France)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE;

ADULT; AGGRESSIVE RELAPSING REMITTING MULTIPLE SCLEROSIS; ALOPECIA; AMENORRHEA; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG FEVER; DRUG RESPONSE; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLU LIKE SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMAGE ANALYSIS; INJECTION SITE REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 80855131644     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2010.229724     Document Type: Article

References (31)

1. Anon. Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicentre, randomised, double blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group (IMSSG). Neurology 1993;43:655-61.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon-beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94. (Pubitemid 26100751)
3. Anon. Randomised double-blind placebo controlled study of Interferon-beta-1a in relapsing-remitting MS. PRISMS (Prevention of Relapses and Disability by Interferon-beta-1a Subcutaneously in MS) Study Group. Lancet 1998;352:1498-504.
4. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Results of a phase III multicenter, double blind, placebo-controlled trial. Neurology 1995;45:1268-76.
5. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-25. (Pubitemid 36026580)
6. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-18. (Pubitemid 27090928)
7. Polman CH, O'Connor PW, Havrdova E, et al. A randomised, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
8. Wiendl H, Toyka KV, Rieckmann P, et al.; Multiple Sclerosis Therapy Consensus Group (MSTCG). Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008;255:1449-63.
9. Bar-Or A, Oger J, Gibbs E, et al. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? Mult Scler 2009;15:959-64.
10. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomised placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-9. (Pubitemid 27099852)
11. Vollmer T, Panitich H, Bar-Or A, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Multiple Scler 2008;14:663-70. (Pubitemid 351954409)
12. Le Page E, Leray E, Taurin G, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008;79:52-6.
13. Debouverie M, Taillandier L, Pittion-Vouyovitch S, et al. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment. Mult Scler 2007;13:626-31. (Pubitemid 46939529)
14. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31. (Pubitemid 13158528)
15. Miller DH, Barkhof F, Berry I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-8.
16. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
17. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis Brain 2010;133:1900-13.
18. Coles AJ, Compston DA, Selmaj KW, et al.; The CAMMS223 Trial Investigators. Alemtuzumab vs Interferon-beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801.
19. Fox EJ. Mechanism of action of mitoxantrone. Neurology 2004;63(Suppl 6): S15-18. (Pubitemid 40019273)
20. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002;59:909-13.
21. Feuillet L, Guedj E, Eusebio A, et al. Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis. Rev Neurol (Paris) 2003;159:1169-72. (Pubitemid 38133563)
22. Gofette S, Van Pesch V, Vanoverschelde JL, et al. Severe delayed heart failure in three multiple sclerosis previously treated with mitoxantrone. J Neurol 2005;252:1217-22. (Pubitemid 41443622)
23. Vicari AM, Ciceri F, Folli F, et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 1998;12:441-2. (Pubitemid 28138231)
24. Ghalie RG, Mauch E, Edan G, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002;8:441-5.
25. Brassat D, Recher C, Waubant E, et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002;59:954-5.
26. Comment in: Neurology 2003;60(8):1399-400; author reply 1400.
27. Delisse B, de Seze J, Mackowiak A, et al. Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. Mult Scler 2004;10:92. Comment on: Mult Scler 2003;9(2):213-14.
28. Nollet S, Berger E, Deconinck E, et al. Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone. Rev Neurol (Paris) 2006;162:195-9.
29. Ellis R, Boggild M. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? Mult Scler 2009;15:505-8.
30. Le Page E, Leray E, Brochet B, et al. Long-term safety profile of Mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler 2011;17:867-75.
31. Rivera V, Weinstock-Guttman B, Beagan J, et al. Final results from Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis study (RENEW). Mult Scler 2009;15:S254.